

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

## **M. 7746 - TEVA / ALLERGAN GENERICS**

### **SECTION 1.2**

#### **Description of the concentration**

On 21 January 2016, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004. Under the terms of the proposed concentration, Teva Pharmaceutical Industries Limited (“Teva”) intends to acquire sole control of the global generic pharmaceuticals business of Allergan plc, including the U.S. and international generic commercial units, third-party supplier Medis, global generic manufacturing operations, the global generic R&D unit, the international over-the-counter (“OTC”) commercial unit (excluding OTC eye care products) and some established international brands (together “Allergan Generics Business”).

The areas of activities of the undertakings concerned are as follows:

- **Teva:** development, manufacturing, marketing, sale and distribution of generic and proprietary pharmaceutical products as well as biopharmaceuticals and active pharmaceutical ingredients worldwide.
- **Allergan Generics Business:** Allergan Generics Business comprises the global generics business of Allergan plc, including the U.S. and international generic commercial units, third-party supplier Medis, global generic manufacturing operations, the global generic R&D unit, the international OTC commercial unit (excluding OTC eye care products) and some established international brands.